BB Biotech AG (BBZA.DE)
EUR 39.05
(0.77%)
EUR 39.05
(0.77%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | -2.63 Billion CHF | 0.0% |
| 2022 | - CHF | 0.0% |
| 2021 | - CHF | 100.0% |
| 2020 | -3.95 Billion CHF | 0.0% |
| 2019 | - CHF | 100.0% |
| 2018 | -3.06 Billion CHF | 0.0% |
| 2017 | - CHF | 100.0% |
| 2016 | -3.21 Billion CHF | 21.99% |
| 2015 | -4.12 Billion CHF | 0.0% |
| 2014 | - CHF | 0.0% |
| 2013 | - CHF | 0.0% |
| 2012 | - CHF | 0.0% |
| 2011 | - CHF | 0.0% |
| 2010 | - CHF | 0.0% |
| 2009 | - CHF | 0.0% |
| 2008 | - CHF | 0.0% |
| 2007 | - CHF | 0.0% |
| 2006 | - CHF | 0.0% |
| 2005 | - CHF | 0.0% |
| 2004 | - CHF | 0.0% |
| 2003 | - CHF | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | - CHF | 100.0% |
| 2024 Q1 | -2.82 Billion CHF | -7.24% |
| 2023 Q3 | - CHF | 100.0% |
| 2023 Q4 | -2.63 Billion CHF | 0.0% |
| 2023 FY | -2.63 Billion CHF | 0.0% |
| 2023 Q2 | -2.57 Billion CHF | 0.0% |
| 2023 Q1 | - CHF | 0.0% |
| 2022 Q1 | - CHF | 0.0% |
| 2022 Q2 | - CHF | 0.0% |
| 2022 Q3 | - CHF | 0.0% |
| 2022 Q4 | - CHF | 0.0% |
| 2022 FY | - CHF | 0.0% |
| 2021 Q2 | - CHF | 0.0% |
| 2021 Q4 | - CHF | 0.0% |
| 2021 Q3 | - CHF | 0.0% |
| 2021 Q1 | - CHF | 0.0% |
| 2021 FY | - CHF | 100.0% |
| 2020 Q2 | - CHF | 0.0% |
| 2020 Q1 | - CHF | 0.0% |
| 2020 Q3 | - CHF | 0.0% |
| 2020 Q4 | - CHF | 0.0% |
| 2020 FY | -3.95 Billion CHF | 0.0% |
| 2019 Q2 | - CHF | 0.0% |
| 2019 Q1 | - CHF | 0.0% |
| 2019 FY | - CHF | 100.0% |
| 2019 Q4 | - CHF | 0.0% |
| 2018 Q3 | - CHF | 0.0% |
| 2018 FY | -3.06 Billion CHF | 0.0% |
| 2018 Q2 | - CHF | 0.0% |
| 2018 Q1 | - CHF | 0.0% |
| 2018 Q4 | - CHF | 0.0% |
| 2017 Q2 | -3.33 Billion CHF | 5.37% |
| 2017 Q1 | -3.52 Billion CHF | -9.62% |
| 2017 FY | - CHF | 100.0% |
| 2017 Q4 | - CHF | 0.0% |
| 2017 Q3 | - CHF | 100.0% |
| 2016 FY | -3.21 Billion CHF | 21.99% |
| 2016 Q3 | - CHF | 100.0% |
| 2016 Q1 | -2.93 Billion CHF | 28.78% |
| 2016 Q2 | -2.96 Billion CHF | -0.97% |
| 2016 Q4 | -3.21 Billion CHF | 0.0% |
| 2015 Q3 | - CHF | 100.0% |
| 2015 Q4 | -4.12 Billion CHF | 0.0% |
| 2015 FY | -4.12 Billion CHF | 0.0% |
| 2015 Q1 | -3.73 Billion CHF | 0.0% |
| 2015 Q2 | -3.93 Billion CHF | -5.35% |
| 2014 Q3 | -2.9 Billion CHF | -18.77% |
| 2014 FY | - CHF | 0.0% |
| 2014 Q4 | - CHF | 100.0% |
| 2014 Q2 | -2.44 Billion CHF | -7.85% |
| 2014 Q1 | -2.26 Billion CHF | 0.0% |
| 2013 Q4 | - CHF | 100.0% |
| 2013 FY | - CHF | 0.0% |
| 2013 Q1 | -1.64 Billion CHF | 0.0% |
| 2013 Q3 | -2.16 Billion CHF | -22.77% |
| 2013 Q2 | -1.76 Billion CHF | -6.85% |
| 2012 Q4 | - CHF | 0.0% |
| 2012 FY | - CHF | 0.0% |
| 2012 Q1 | - CHF | 0.0% |
| 2012 Q2 | - CHF | 0.0% |
| 2012 Q3 | - CHF | 0.0% |
| 2011 FY | - CHF | 0.0% |
| 2011 Q2 | - CHF | 0.0% |
| 2011 Q3 | - CHF | 0.0% |
| 2011 Q4 | - CHF | 0.0% |
| 2011 Q1 | - CHF | 0.0% |
| 2010 FY | - CHF | 0.0% |
| 2010 Q2 | - CHF | 0.0% |
| 2010 Q1 | - CHF | 0.0% |
| 2010 Q4 | - CHF | 0.0% |
| 2010 Q3 | - CHF | 0.0% |
| 2009 FY | - CHF | 0.0% |
| 2009 Q4 | - CHF | 0.0% |
| 2008 FY | - CHF | 0.0% |
| 2007 FY | - CHF | 0.0% |
| 2006 FY | - CHF | 0.0% |
| 2005 FY | - CHF | 0.0% |
| 2004 FY | - CHF | 0.0% |
| 2003 FY | - CHF | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| BioNTech SE | 357.7 Million EUR | 837.113% |
| CureVac N.V. | 24.82 Million EUR | 10722.479% |
| Biotest Aktiengesellschaft | 419.1 Million EUR | 729.123% |
| Biotest Aktiengesellschaft | 419.1 Million EUR | 729.123% |
| BRAIN Biotech AG | 9.72 Million EUR | 27209.326% |
| Formycon AG | 467 Thousand EUR | 564693.79% |
| Heidelberg Pharma AG | 10.48 Million EUR | 25240.211% |
| Medigene AG | 1.00 EUR | 263665300100.0% |